文献速递青光眼

全身抗高血压药物与眼压及青光眼关联的系统综述与Meta分析

A Systematic Review and Meta-analysis of Systemic Antihypertensive Medications With Intraocular Pressure and Glaucoma.
PubMed 文献 · Am J Ophthalmol · 2023-03-24

本系统综述与Meta分析检索至2022年12月5日的文献,纳入11项研究(10项进入Meta分析),评估β受体阻滞剂、钙通道阻滞剂、血管紧张素转换酶抑制剂、血管紧张素受体阻滞剂和利尿剂与青光眼或眼压的关联。β受体阻滞剂与较低的青光眼 odds 相关(OR 0.83,95%CI 0.75-0.92,7项研究,n=219,535)且与较低眼压相关(β -0.53,95%CI -1.05至-0.02,3项研究,n=28,683);钙通道阻滞剂与较高的青光眼 odds 相关(OR 1.13,95%CI 1.03-1.24,7项研究,n=219,535)但与眼压无关(β -0.11,95%CI -0.25至0.03,2项研究,n=20,620)。

要点

  • β受体阻滞剂与较低的青光眼 odds 相关(OR 0.83,95%CI 0.75-0.92)且与较低眼压相关(β -0.53,95%CI -1.05至-0.02)。
  • 钙通道阻滞剂与较高的青光眼 odds 相关(OR 1.13,95%CI 1.03-1.24)但与眼压无显著关联(β -0.11,95%CI -0.25至0.03)。
  • ACEI、ARB或利尿剂与青光眼或眼压无一致关联。

核心结论

  • 全身抗高血压药物对青光眼和眼压的影响存在异质性。
  • 临床医生应意识到全身抗高血压药物可能掩盖眼压升高或对青光眼风险产生正面或负面影响。

研究设计与样本

  • 系统综述与Meta分析,检索数据库截至2022年12月5日。
  • 纳入标准为研究全身抗高血压药物与青光眼的关联,或与无青光眼或高眼压症者眼压的关联。
  • 方案在PROSPERO注册(注册号CRD42022352028)。
  • 共纳入11项研究,其中10项进入Meta分析;3项眼压研究为横断面研究,8项青光眼研究主要为纵向研究。

主要发现

  • β受体阻滞剂与较低的青光眼 odds 相关(OR 0.83,95%CI 0.75-0.92,7项研究,n=219,535)。
  • β受体阻滞剂与较低的眼压相关(β -0.53,95%CI -1.05至-0.02,3项研究,n=28,683)。
  • 钙通道阻滞剂与较高的青光眼 odds 相关(OR 1.13,95%CI 1.03-1.24,7项研究,n=219,535)。
  • 钙通道阻滞剂与眼压无显著关联(β -0.11,95%CI -0.25至0.03,2项研究,n=20,620)。
  • ACEI、ARB或利尿剂与青光眼或眼压无一致关联。

临床怎么用

  • 临床医生应意识到全身抗高血压药物可能掩盖眼压升高或对青光眼风险产生正面或负面影响。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We synthesized the literature on the association between systemic antihypertensive medications with intraocular pressure (IOP) and glaucoma. Antihypertensive medications included β-blockers, calcium channel blockers, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and diuretics. DESIGN: Systematic review and meta-analysis. METHODS: Databases were searched for relevant articles until December 5, 2022. Studies were eligible if they examined (1) the association between systemic antihypertensive medications with glaucoma or (2) the association between systemic antihypertensive medications with IOP in those without glaucoma or ocular hypertension. The protocol was registered at PROSPERO (International Prospective Register of Systematic Reviews; registration ID: CRD42022352028). RESULTS: A total of 11 studies were included in the review and 10 studies in the meta-analysis. The 3 studies on IOP were cross-sectional, whereas the 8 studies on glaucoma were primarily longitudinal. In the meta-analysis, β-blockers were associated with a lower odds of glaucoma (odds ratio: 0.83, 95% CI: 0.75-0.92, 7 studies, n = 219,535) and lower IOP (β: -0.53, 95% CI: -1.05 to -0.02, 3 studies, n = 28,683). Calcium channel blockers were associated with a higher odds of glaucoma (odds ratio: 1.13, 95% CI: 1.03-1.24, 7 studies, n = 219,535) but not with IOP (β: -0.11, 95% CI: -0.25 to 0.03, 2 studies, n = 20,620). There were no consistent associations between angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or diuretics with glaucoma or IOP. CONCLUSIONS: Systemic antihypertensive medications have heterogeneous effects on glaucoma and IOP. Clinicians should be aware that systemic antihypertensive medications may mask elevated IOP or positively or negatively affect the risk of glaucoma.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Leung G, Grant A, Garas AN, et al. A Systematic Review and Meta-analysis of Systemic Antihypertensive Medications With Intraocular Pressure and Glaucoma. Am J Ophthalmol. 2023. PMID: 36966883. doi:10.1016/j.ajo.2023.03.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。